Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KOD Kodiak Sciences Inc.

Post-Market Trading 03-25 17:01:36 EDT

3.21

-0.31

-8.95%

盘后3.20

+0.00-0.16%

17:00 EDT

High3.49	Low3.13	Vol355.18K
Open3.49	D1 Closing3.52	Amplitude10.37%
Mkt Cap168.27M	Tradable Cap103.25M	Total Shares52.50M
T/O1.15M	T/O Rate1.10%	Tradable Shares32.21M
P/B0.91	ROE-78.57%	EPS-3.65
52wk High11.60	52wk Low2.19	P/E-0.88
Dividend0.00	Div.Yield0.00	ROA-27.71%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"KOD","market":"US","secType":"STK","nameCN":"Kodiak Sciences Inc.","latestPrice":3.205,"timestamp":1742932800000,"preClose":3.52,"halted":0,"volume":355184,"hourTrading":{"tag":"盘后","latestPrice":3.2,"preClose":3.205,"latestTime":"17:00 EDT","volume":551,"amount":1765.4900662,"timestamp":1742936450907},"delay":0,"floatShares":32214858,"shares":52501425,"eps":-3.646996,"marketStatus":"Post-Market Trading","change":-0.315,"latestTime":"03-25 17:01:36 EDT","open":3.49,"high":3.49,"low":3.125,"amount":1150473.7950016,"amplitude":0.103693,"askPrice":3.57,"askSize":25,"bidPrice":3.13,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-3.646996,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1742947200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":3.52,"postHourTrading":{"tag":"盘后","latestPrice":3.2,"preClose":3.205,"latestTime":"17:00 EDT","volume":551,"amount":1765.4900662,"timestamp":1742936450907},"volumeRatio":0.975724,"impliedVol":1.5196,"impliedVolPercentile":0.88},"requestUrl":"/m/hq/s/KOD","defaultTab":"news","newsList":[{"id":"2521235657","title":"Kodiak Sciences Inc  expected to post a loss of 88 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521235657","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521235657?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:37","pubTimestamp":1742819826,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc  expected to post a loss of88cents a share - Earnings Preview Kodiak Sciences Inc KOD.OQ KOD.O is expected to show no change in quarterly revenue when it reports  results on March ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL5N3Q70Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"gpt_icon":0},{"id":"2521714099","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714099?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Comp de San Bas                                  4Q       .36       AMC. ·Oklo Inc. Class A                               4Q      (.07)      AMC. ·Core & Main Inc.                                 4Q       .36       BMO. ·McCormick & Co                                 1Q       .64   6:30 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SDST","CNXC","PAYX","ALUR","CTAS","PAYS","ABL","CHWY","SLRN","UNCY","CDLR","NUTX","MLKN","WOOF","TEN","DLTR","GOVX","CRMD","KBH","EDAP","PDSB","WBA","ACRV","BCAB","ANTX","IOBT","OBIO","IVA","ZURA","RLMD","XFOR","DERM","SCS","SKYX","MDAI","MREO","THRD","MKC","IKT","WGO","RVPH","LPTX","BEEM","SURG","KOD","FBIO","CALC","CLSD","AFMD","GRDN"],"gpt_icon":0},{"id":"2518072238","title":"KOD Completes Enrollment in Phase III Study for Eye Disease Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518072238","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518072238?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 22:39","pubTimestamp":1741703940,"startTime":"0","endTime":"0","summary":"Kodiak SciencesKOD announced that it has completed enrollment in a late-stage study of tarcocimab tedromer in patients with diabetic retinopathy . Per KOD, more than 250 patients have been enrolled in the phase III GLOW2 study, surpassing the initial enrollment target. With a 48-week treatment duration, all patients are expected to complete their primary endpoint visits by the end of January 2026. The top-line clinical data is anticipated to be announced in the first quarter of 2026.In late 2023, Kodiak rebooted the development program of tarcocimab following positive phase III results from the GLOW1 study, which evaluated the treatment in patients with moderately severe to severe non-proliferative diabetic retinopathy. Leveraging the GLOW1 study's success, Kodiak initiated the GLOW2 study to further investigate tarcocimab for DR and began dosing patients in May 2024. Enrolled DR patients will receive tarcocimab on extended dosing intervals, including six-month dosing for all patients.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kod-completes-enrollment-phase-iii-143900570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2098885051.SGD","LU0719512351.SGD","BK4585","GILD","BK4550","LU1316542783.SGD","LU1951198990.SGD","LU0642271901.SGD","LU2468319806.SGD","IE00B19Z3581.USD","BK4583","BK4612","LU0889565916.HKD","LU2458330243.SGD","BK4573","LU1839511570.USD","IE00BSNM7G36.USD","LU0082616367.USD","LU1880398554.USD","LU1951200564.SGD","BK4575","BMRN","LU2458330169.SGD","LU0127658192.USD","LU2250418816.HKD","LU2089984988.USD","BK4141","LU0056508442.USD","LU1803068979.SGD","LU1988902786.USD","LU0823434583.USD","LU0889565833.HKD","LU1559883803.SGD","LU1923623000.USD","IE00B19Z3B42.SGD","LU0109394709.USD","CORT","BK4578","LU1066051498.USD","BK4554","LU0390134368.USD","LU2360106780.USD","BK4614","III","IE0009356076.USD","IE00B3T34201.USD","KOD","LU2054465674.USD","LU0320765992.SGD"],"gpt_icon":1},{"id":"2518785975","title":"Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2518785975","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518785975?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:46","pubTimestamp":1741639568,"startTime":"0","endTime":"0","summary":"Kodiak Sciences (KOD) announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabet...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-completes-enrollment-in-glow2-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-completes-enrollment-in-glow2-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","KOD","BK4139"],"gpt_icon":0},{"id":"2518578368","title":"Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients With Diabetic Retinopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518578368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518578368?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:39","pubTimestamp":1741639166,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUA17X3YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","KOD","BK4139"],"gpt_icon":0},{"id":"2518786946","title":"Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518786946","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518786946?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:38","pubTimestamp":1741639080,"startTime":"0","endTime":"0","summary":"Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance. PALO ALTO, Calif., March 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. , today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy .The Phase 3 GLOW2 study is a prospective, randomized, double-masked, multi-center pivotal superiority study designed to evaluate the efficacy and safety of tarcocimab tedromer in treatment-nave patients with diabetic retinopathy . Patients are randomized 1:1 and receive either sham injections or tarcocimab via intravitreal injection at baseline, Week 4, Week 8, Week 20 and Week 44. The primary endpoint is the proportion","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kodiak-sciences-completes-enrollment-second-203800919.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-sciences-completes-enrollment-second-203800919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU1803068979.SGD","LU1951200564.SGD","BK4139","LU0719512351.SGD","LU2264538146.SGD","IE00B5949003.HKD","LU0979878070.USD","BK4505","LU0082616367.USD","GFS","BK4612","LU2458330169.SGD","BK4566","LU0889565833.HKD","LU0642271901.SGD","BK4532","LU1242518931.SGD","LU1989764664.SGD","BK4588","LU0198837287.USD","LU2054465674.USD","LU2250418816.HKD","BK4141","BK4614","LU0823421416.USD","BK4512","BK4529","IE0004445239.USD","LU1242518857.USD","LU1880398471.USD","LU1988902786.USD","LU1923623000.USD","LU1951198990.SGD","IE0009356076.USD","LU0823434583.USD","LU1316542783.SGD","LU1064131342.USD","IE00BMPRXR70.SGD","BK4543","BK4575","BK4605","KOD","LU0056508442.USD","LU2360106780.USD","LU0823421333.USD","LU0390134368.USD","LU0109392836.USD","LU1852331112.SGD"],"gpt_icon":1},{"id":"2517393833","title":"Kodiak Sciences granted orphan designation for tabirafusp alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2517393833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517393833?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 07:11","pubTimestamp":1741129867,"startTime":"0","endTime":"0","summary":"Kodiak Sciences (KOD)’ tabirafusp alfa was granted FDA orphan designation as a treatment of uveitic macular edema, according to a post to the agenc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-granted-orphan-designation-for-tabirafusp-alfa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-granted-orphan-designation-for-tabirafusp-alfa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","KOD"],"gpt_icon":0},{"id":"2514018713","title":"We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514018713","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514018713?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 22:29","pubTimestamp":1740493742,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.So should Kodiak Sciences  shareholders be worried about its cash burn?For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.When Might Kodiak Sciences Run Out Of Money?How Is Kodiak Sciences' Cash Burn Changing Over Time?Kodiak Sciences has a market capitalisation of US$234m and burnt through US$147m last year, which is 63% of the company's market value. Given how large that cash bu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-keeping-eye-kodiak-sciences-142902723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","USJW.SI","KOD","BK4505","IE00BKPKM429.USD","TSYW.SI","LU2095319765.USD",".IXIC","NVIW.SI","LU2210149790.SGD","QLD","BK4588","BK4585","MNQmain","QID","USAW.SI","NQmain","PSQ","LU2210150020.SGD","BK4139","SQQQ","TQQQ"],"gpt_icon":1},{"id":"2510434904","title":"Canaccord Genuity Sticks to Their Buy Rating for Kodal Minerals (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510434904","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510434904?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 15:45","pubTimestamp":1739346332,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alexander Bedwany from Canaccord Genuity reiterated a Buy rating on Kodal Minerals (KOD – Research Report), with a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-kodal-minerals-kod?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-kodal-minerals-kod?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KOD","MTX"],"gpt_icon":0},{"id":"2508553884","title":"Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2508553884","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508553884?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 20:30","pubTimestamp":1738672200,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., Feb. 4, 2025 /PRNewswire/ --Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA.Glaucoma is the leading cause of irreversible blindness, affecting approximately 76 million people worldwide. This optic neuropathy progressively damages the optic nerve, leading to partial or total vision loss. Emerging research identifies neuroinflammation as a key driver of optic neuropathy in glaucoma, but the primary focus of glaucoma therapy today is decreasing the elevated intraocular pressure, the only modifiable risk factor of the disease.Kodiak Sciences is a biopharmaceutical company committed to researching, developing, and commercializing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kodiak-sciences-present-glaucoma-360-123000753.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-sciences-present-glaucoma-360-123000753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FET","BK4505","BK4179","KOD","BK4139"],"gpt_icon":0},{"id":"2503055417","title":"Here’s Why Kodiak Sciences Inc. (KOD) Is Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2503055417","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503055417?lang=en_us&edition=full_marsco","pubTime":"2025-01-14 05:26","pubTimestamp":1736803569,"startTime":"0","endTime":"0","summary":"One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers. That’s why we decided to take a look at some of the recent past winners in this article. These 24 companies, predominantly involved in the quantum computing, biotechnology, and technology sectors, have performed significantly well in the final quarter of 2024, registering spectacular returns over the 3 months.That said, let’s take a look at the top 24 stocks that have skyrocketed and pose a solid growth opportunity in the coming year. We will also explore how well the stocks have performed throughout the year and what they have in store for 2025.To come up with 24 names, we considered only the stocks that have at least $2 billion in market capitalization and have registered commendable returns in the fourth quarter of 2024.A close up of a scientist in a labcoat admiring the progress of a biotech experiment.Disclosure: None. This article ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-kodiak-sciences-inc-kod-212609196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","KOD","BK4139"],"gpt_icon":0},{"id":"2501025191","title":"KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2501025191","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501025191?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 21:59","pubTimestamp":1736171940,"startTime":"0","endTime":"0","summary":"Shares of Kodiak Sciences KOD have skyrocketed 270.7% in the past six months fueled by updates from the developmental program of its lead investigational candidate, tarcocimab. It is a novel anti-VEGF antibody biopolymer conjugate, which is being evaluated for treating retinal vascular diseases.In late 2023, Kodiak rebooted the development program of tarcocimab following positive phase III results from the GLOW1 study, which evaluated the treatment in patients with moderately severe to severe non-proliferative diabetic retinopathy. Leveraging the GLOW1 study's success, Kodiak initiated the GLOW2 study in late 2023 to further investigate tarcocimab for diabetic retinopathy  and began dosing patients in May 2024, with enrollment expected to be completed soon. The success of the GLOW2 study is expected to serve as the basis for a single biologics license application submission for tarcocimab, seeking its approval for DR.The revival of tarcocimab in Kodiak's pipeline, after a major setback","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kod-stock-rallies-271-6-135900100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4505","CSTL","BK4196","KOD","CTMX","VNDA"],"gpt_icon":0},{"id":"2494534876","title":"Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2494534876","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494534876?lang=en_us&edition=full_marsco","pubTime":"2024-12-28 22:18","pubTimestamp":1735395494,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies Kodiak Sciences' stock price is sensitive to their trading actions. 52% of the business is held by the top 5 shareholders. Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company. If you want to know who really controls Kodiak Sciences Inc. , then you'll have to look at the makeup of its share registry. With 43% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential .Last week’s 15% gain means that institutional investors were on the positive end of the spectrum even as the company has shown strong longer-term trends. The gains from last week would have further boosted the one-year return to shareholders which currently stand at 228%.In the chart below, we zoom in on the different ownership groups of Kodiak Sciences.While studying institutional ownership for a company can add value to your research, it","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/institutional-investors-lot-riding-kodiak-141814397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","LU2210149790.SGD","BK4139","NQmain","USAW.SI","TSYW.SI","NDAQ","BK4505","PSQ","IE00B3QW5Z07.USD","USJW.SI","BK4112","IE00BKPKM429.USD","SQQQ","MNQmain","QID","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","QLD","IE00BGHQF748.EUR","NVIW.SI","KOD","TQQQ",".IXIC","BK4588"],"gpt_icon":1},{"id":"2494451860","title":"What Awaits These 4 Biotech Stocks That More Than Doubled in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2494451860","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494451860?lang=en_us&edition=full_marsco","pubTime":"2024-12-26 23:29","pubTimestamp":1735226940,"startTime":"0","endTime":"0","summary":"The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This slowdown was primarily due to disappointing third-quarter earnings, reduced guidance and pipeline setbacks. These challenges highlighted the inherent volatility in biotech, amplified by broader macroeconomic uncertainties. Despite these setbacks, the demand for cutting-edge medical innovations ensures the sector remains a focal point for investors.Looking ahead, innovation will continue to be a key growth driver, particularly in high-potential areas like obesity and oncology treatments. The sector's robust fundamentals and expectations of strong M&A activity in 2025 indicate a promising outlook. While the current environment may deter some, the long-term need for advanced medicines is expected to draw investors back to the sector, reinforcing its importance in the healthcare landscape.As we approach the New Year, let us take a good look at some biotech companies likeAr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/awaits-4-biotech-stocks-more-152900258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARQT","MSB.AU","BK4505","KOD","MNPR","MESO","BK4139"],"gpt_icon":0},{"id":"2493754800","title":"Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2493754800","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493754800?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 20:42","pubTimestamp":1734957721,"startTime":"0","endTime":"0","summary":"Shares of Rumble Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/24/12/42644814/why-rumble-shares-are-trading-higher-by-around-43-here-are-20-stocks-moving-premarket","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","MNQmain","SQQQ","BK4133","TPIC","ATXS","USJW.SI","QLD","EDBL","BK4077","TQQQ","APTO","JDZG","TSYW.SI","BK4555","CDT","QID","RELI","BK4099","RUM","BK4141","BK4585","BK4007","BK4139","ONFO","BK4096","BK4505","BNRG","HSDT","BK4173","NQmain","CNTM","CLB","BK4082","USAW.SI","KOD",".IXIC","HMC","BK4179","BK4023","NSANY","BK4583","NVIW.SI","ABAT","PSQ","SIGA","BK4121","AILE"],"gpt_icon":1},{"id":"2490804525","title":"KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2490804525","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490804525?lang=en_us&edition=full_marsco","pubTime":"2024-12-10 23:43","pubTimestamp":1733845380,"startTime":"0","endTime":"0","summary":"Shares of Kodiak Sciences KOD rallied 29.6% on Monday after an eminent financial services company, Jefferies, upgradedKOD to a “BUY” rating stating that the company has a major “turnaround story” in place for 2025. Kodiak has lately been garnering immense investor attention driven by the significant potential of its ongoing late-stage studies on the lead candidate, tarcocimab, for retinal disease indications and other pipeline programs.Tarcocimab, a novel anti-VEGF antibody biopolymer conjugate, is being developed for diabetic eye disease and wet age-related macular degeneration .Let us dig deeper into the catalysts behind Jefferies’ optimism regarding the growth of Kodiak Sciences in the near future.Following the successful phase I study, Kodiak is preparing to advance KSI-501 into phase III through the DAYBREAK study, which will assess its efficacy, durability and safety for wet AMD. The company also plans to study tarcocimab as a second investigational arm in the DAYBREAK study for","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kod-stock-jefferies-upgrades-rating-154300188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KOD","PFE"],"gpt_icon":0},{"id":"2490365030","title":"Kodiak Sciences, Nona Biosciences partner on next-gen antibody therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2490365030","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490365030?lang=en_us&edition=full_marsco","pubTime":"2024-12-10 10:50","pubTimestamp":1733799007,"startTime":"0","endTime":"0","summary":"The company states: “Nona Biosciences announced a collaboration with Kodiak Sciences (KOD). This partnership aims to advance the discovery of novel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-nona-biosciences-partner-on-next-gen-antibody-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-nona-biosciences-partner-on-next-gen-antibody-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","KOD"],"gpt_icon":0},{"id":"2490868701","title":"Sector Update: Health Care Stocks Edge Higher Monday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2490868701","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490868701?lang=en_us&edition=full_marsco","pubTime":"2024-12-10 02:48","pubTimestamp":1733770105,"startTime":"0","endTime":"0","summary":"Health care stocks were edging up Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  each adding 0.2%.The iShares Biotechnology ETF  rose 0.5%.In corporate news, Sonnet BioTherapeutics  shares surged past 47%. The company said Monday its phase 1 trial of SON-1010 demonstrated a partial response and disease stabilization in adult patients with advanced solid tumors.Kodiak Sciences  shares jumped 27% after Jefferies upgraded the company's rating to buy from hold. Jefferies also raised its price target for the stock to $20 from $6.Revance Therapeutics  and Crown Laboratories said Monday they amended their merger agreement to reduce Crown's tender offer for all outstanding Revance shares to $3.10 apiece in response to a dispute with Teoxane. Revance shares tumbled 20%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","BK4505","RVNC","BK4585","BK4588","KOD","BK4007","XLV","BK4139","LU0053671581.USD","SONN","IBB"],"gpt_icon":0},{"id":"2490062227","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2490062227","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490062227?lang=en_us&edition=full_marsco","pubTime":"2024-12-10 02:26","pubTimestamp":1733768773,"startTime":"0","endTime":"0","summary":"LeddarTech  disclosed Monday a collaboration and software license agreement with Texas Instruments  to deliver a platform for advanced driver assistance systems and autonomous driving markets.Shares of LeddarTech surged 311% as intraday trading volume soared to over 231.7 million from a daily average of about 291,000.Kodiak Sciences  shares jumped 26% amid heavy trading after Jefferies upgraded the company's rating to buy from hold.Jefferies also raised its price target for the stock to $20 from $6.More than 1.5 million shares of Kodiak traded intraday compared with a daily average of about 293,000.Wells Fargo upgraded RealReal  to overweight from equalweight while adjusting its price target to $15 from $4.Shares of RealReal were up 41% as intraday trading volume catapulted to more than 9.6 million from a daily average of about 2.2 million.Price: 1.28, Change: +0.97, Percent Change: +311.58","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2129689431.USD","BK4533","BK4567","BK4141","LU1244550221.USD","LU0345774631.USD","IE00BZ199S13.USD","BK4139","LU0553294199.USD","IE0009356076.USD","BK4534","BK4561","LU0738911758.USD","LU1721428933.USD","LU0661504455.SGD","BK4585","LU1983260115.SGD","LU2413666699.HKD","BK4554","LU1674673428.USD","REAL","BK4512","BK4588","IE00BFXG0V08.USD","TXN","LU2133065610.SGD","IE00BYQQ9H92.USD","LU0557290698.USD","BK4505","LU0868494617.USD","LU0545039389.USD","BK4023","KOD","LDTC","LU1066053197.SGD","SG9999003800.SGD","LU1823568750.SGD","LU1003077747.HKD","LU1235294995.USD","LU2129689514.USD","IE0008368304.USD","LU0312595415.SGD","LU0949170772.SGD","LU1674673691.USD","LU0314104364.USD","BK4122","LU0345774391.USD","SG9999011175.SGD","LU1244550494.USD","BK4094"],"gpt_icon":0},{"id":"2490705059","title":"Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2490705059","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490705059?lang=en_us&edition=full_marsco","pubTime":"2024-12-10 01:33","pubTimestamp":1733765619,"startTime":"0","endTime":"0","summary":"Jefferies has upgraded Kodiak Sciences Inc. , a biopharmaceutical companyfocused on retinal  diseases.Kodiak’s lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases.Tarcocimab is currently being studied in two Phase 3 trials, GLOW2 in diabetic retinopathy and DAYBREAK in patients with wet age-related macular degeneration . Both studies are actively enrolling patients.Jefferies upgraded Kodiak Sciences from Hold to Buy. The analyst writes that Kodiak Sciences is gaining investor interest as it enters a pivotal phase.The company’s turnaround story for 2025 looks promising, with Phase 3 trials in wet AMD progressing well and showing strong potential.Adding to the excitement, upcoming VEGF/IL-6 data for macular edema secondary to inflammation   could open doors to new indications, enhancing its growth prospects.Jefferies writes that at $7 per share and a $400 million market cap, the stock app","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6X6SIbdMLtBlYaKW9uo3Fg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/9beb10dfefd4de43e2f5a0eeb10f17b6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6X6SIbdMLtBlYaKW9uo3Fg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/9beb10dfefd4de43e2f5a0eeb10f17b6"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eye-disease-focused-kodiak-sciences-173339813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KOD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kodiak.com","stockEarnings":[{"period":"1week","weight":0.0203},{"period":"1month","weight":-0.209},{"period":"3month","weight":-0.6434},{"period":"6month","weight":0.3538},{"period":"1year","weight":-0.4368},{"period":"ytd","weight":-0.6462}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":-0.0431},{"period":"3month","weight":-0.0453},{"period":"6month","weight":0.0071},{"period":"1year","weight":0.1014},{"period":"ytd","weight":-0.0205}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.06094},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.132442},{"month":3,"riseRate":0,"avgChangeRate":-0.123362},{"month":4,"riseRate":0.5,"avgChangeRate":-0.092981},{"month":5,"riseRate":0.666667,"avgChangeRate":0.125856},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015307},{"month":7,"riseRate":0.5,"avgChangeRate":-0.036052},{"month":8,"riseRate":0.5,"avgChangeRate":-0.040602},{"month":9,"riseRate":0.666667,"avgChangeRate":0.013919},{"month":10,"riseRate":0.666667,"avgChangeRate":0.230496},{"month":11,"riseRate":0.714286,"avgChangeRate":0.300587},{"month":12,"riseRate":0.571429,"avgChangeRate":0.273501}],"exchange":"NASDAQ","name":"Kodiak Sciences Inc.","nameEN":"Kodiak Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kodiak Sciences Inc.,KOD,Kodiak Sciences Inc.股票,Kodiak Sciences Inc.股票老虎,Kodiak Sciences Inc.股票老虎国际,Kodiak Sciences Inc.行情,Kodiak Sciences Inc.股票行情,Kodiak Sciences Inc.股价,Kodiak Sciences Inc.股市,Kodiak Sciences Inc.股票价格,Kodiak Sciences Inc.股票交易,Kodiak Sciences Inc.股票购买,Kodiak Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction